Invention Grant
- Patent Title: Pharmaceutical compositions for colon-specific delivery
-
Application No.: US15703172Application Date: 2017-09-13
-
Publication No.: US10588864B2Publication Date: 2020-03-17
- Inventor: Lianli Li
- Applicant: Gateway Pharmaceutical LLC
- Applicant Address: US MO Chesterfiled
- Assignee: Gateway Pharmaceuticals LLC
- Current Assignee: Gateway Pharmaceuticals LLC
- Current Assignee Address: US MO Chesterfiled
- Agency: Florek & Endres PLLC
- Main IPC: A61K9/48
- IPC: A61K9/48 ; A61K9/20 ; A61K9/28 ; A61K31/4164 ; A61K9/00

Abstract:
Disclosed are pharmaceutical particulates which release a pharmaceutical compound into the colon following oral administration. A particulate comprises a core comprising a pharmaceutical compound, an inner coating surrounding the core, wherein the inner coating comprises a pharmaceutically acceptable polysaccharide that is susceptible to enzymatic digestion by one or more enzymes present colonic microflora, and an outer coating surrounding the inner coating, wherein the outer coating comprises a polymer which is stable at upper gastrointestinal pH but can dissolve at pH>6. The core of a particulate can further comprise an excipient such as a diluent, a binder, a disintegrant, a lubricant, a glidant or a combination thereof. Particulates can comprise pharmaceutical compounds for treating colonic diseases such as C. difficile infection, ulcerative colitis, colon cancer, and Crohn's disease.
Public/Granted literature
- US20180000740A1 PHARMACEUTICAL COMPOSITIONS FOR COLON-SPECIFIC DELIVERY Public/Granted day:2018-01-04
Information query